Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial

Yungan Tao; Anne Aupérin; Pierre Blanchard; M. Alfonsi; Xu-Shan Sun; M. Rives; Y. Pointreau; J. Castelli; P. Gräff; S. Wong Hee Kam; Juliette Thariat; Ovidiu Veresezan; S. Heymann; S. Renard-Oldrini; Cédrik Lafond; A. Cornely; Odile Casiraghi; Pierre Boisselier; M. Lapeyre; J. Biau; Jean Bourhis

doi:10.1016/j.radonc.2020.05.021

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Dose-escalated IMRT did not improve LRC in LA-HNSCC patients treated with concomitant CRT over standard 3D-RT. This trial reinforces the evidence showing IMRT reduces xerostomia in LA-HNSCC treated with radiotherapy. Clinicaltrial.gov: NCT00158678.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tao et al. (2020) studied this question.

synapsesocial.com/papers/69d84b5da2a48916bbbefc44 https://doi.org/10.1016/j.radonc.2020.05.021

View Full Paper

Ask AI

Bookmark

Share

Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial

Ask about this paper

Abstract

Discussion

Cite This Study

Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading